Flavobacterium meningosepticum is an unusual, highly resistant, gram-negative bacillus that is associated with neonatal meningitis and nursery outbreaks of meningitis. The optimal therapy for this infection is not known. We successfully treated three neonates with intravenous vancomycin and rifampin. We determined the in vitro activity of meropenem, ciprofloxacin, vancomycin, linezolid (PNU-100766), and rifampin, alone and in combination, against four isolates of F. meningosepticum from neonates with sepsis and meningitis. MICs were determined by tube dilution, and fractional inhibitory concentrations were calculated with use of the checkerboard microtiter dilution technique. Synergy was observed between rifampin and vancomycin against three isolates, while combinations of vancomycin, ciprofloxacin, and linezolid showed an additive effect against all isolates. These results support the clinical evidence that the combination of vancomycin and rifampin is an appropriate regimen for neonatal meningitis due to F. meningosepticum. The combination of meropenem and vancomycin was antagonistic. The clinical efficacy of combinations including ciprofloxacin, newer quinolones, or linezolid for treating F. meningosepticum meningitis deserves further study.
Flavobacterium meningosepticum is an opportunistic gramMethods negative rod of low virulence that is highly resistant to the
Review of Patients' Records
antibiotics commonly used for neonatal sepsis. Neonatal meningitis due to F. meningosepticum is associated with a high A retrospective review of the Pediatric Infectious Diseases Division records at the Baylor College of Medicine (Houston) mortality rate and severe neurological damage. Hydrocephalus is the most common neurological sequela and develops in was performed to identify neonates hospitalized at Texas Children's Hospital and Ben Taub General Hospital with F. menin-ú60% of infants who survive [1] . Delay in implementing appropriate therapy is likely related to the organism's unique gosepticum infection. The complete medical record of each neonate was reviewed. Information concerning gestational age, antimicrobial susceptibility pattern: it is resistant to the antibiotics frequently used for infections due to gram-negative microbirth weight, age, sex, race, hospital course, antibiotic therapy, length of time that blood and CSF cultures were positive, and organisms but susceptible to antimicrobials used for those due to gram-positive pathogens [1, 2] . outcome was obtained. Previous authors have recommended vancomycin and rifampin as the most appropriate combination therapy for treatment of Susceptibility Testing infection due to F. meningosepticum [3] . To further evaluate the therapeutic options for treating F. meningosepticum infection in
Organisms. Four strains of F. meningosepticum, isolated from CSF and blood from four neonates with clinical infection newborns, we reviewed our experience over the last 12 years at Texas Children's Hospital and Harris County Hospital District between 1982 and 1996, were studied. The isolates were identified at the microbiology laboratories of Texas Children's Hosin Houston. In addition, we report the first study of in vitro synergy of various antibiotics against F. meningosepticum. We pital or the Harris County Hospital District by standard bacteriologic techniques. The isolates had been stored frozen in determined the in vitro activity of vancomycin and rifampin alone and in combination as well as the in vitro activity of other antimitrypticase soy broth with 30% glycerol at 070ЊC in the Infectious Diseases Laboratory at Texas Children's Hospital. crobial agents that could offer new alternatives for treatment of F. meningosepticum meningitis.
Antibiotics. The following standard antibiotic powders were provided by their manufacturers: meropenem (Zeneca Pharmaceuticals, Wilmington, DE), linezolid (PNU-100766; Pharmacia & Upjohn Co., Kalamazoo, MI), rifampin (Marion Mer-MICs. MICs were determined in MHB by macrodilution, reports of nursery outbreaks, and review articles were also reviewed for relevant articles. with use of 1 -3 1 10 5 cfu/mL of broth and read after 18 -22 hours of incubation at 35ЊC. The MIC was defined as the lowest concentration at which there was no visible growth. Subcultures Results of tubes were plated on blood agar for determining MBCs.
Antibiotics tested for which National Committee for Clinical
Patients
Laboratory Standards (NCCLS) breakpoints for gram-negative Four neonates with community-acquired F. meningoseptibacteria are available included ciprofloxacin, cefotaxime, tricum infection were hospitalized at Texas Children's Hospital methoprim-sulfamethoxazole (TMP-SMZ), and piperacillin.
or Ben Taub General Hospital between July 1984 and July Microorganisms are considered susceptible when MICs are 1996. The epidemiological, clinical, and laboratory data for the 1 mg/mL and 2/38 mg/mL for ciprofloxacin and TMP-SMZ, four infants are summarized in table 1. The mean birth weight respectively. The breakpoint MICs of cefotaxime and piperacilwas 2,800 g (range, 870 -3,900 g), and all three newborns who lin are 8 mg/mL and 16 mg/mL, respectively. The breakpoint developed meningitis due to F. meningosepticum were full-MIC of meropenem for gram-negative bacteria is 4 mg/mL.
term infants. Three of the neonates were male, and one was Microbroth dilution tests. Synergy tests were performed in female. All patients were Hispanic, and all were delivered by 96-well, U-bottomed sterile plastic microtiter plates (Corning spontaneous vaginal delivery. The clinical manifestations of Laboratory Science Co., Corning, NY). Serial two-fold diluinfection were nonspecific, and all infants had had prior respirations of each antibiotic, alone and in combination, were tested tory symptoms. The mean age of the infants at the time of by using a standard inoculum of 1 -3 1 10 5 cfu. Rifampin and presentation with F. meningosepticum meningitis was 36 days ciprofloxacin were diluted in the wells with 50-mL dilutors, (range, 23 -59 days). The mean duration of bacteremia was 2 with final concentrations ranging from 128 mg/mL to 0.125 days (range, 1 -3 days), and the mean time that CSF cultures mg/mL. Meropenem was diluted from 32 mg/mL to 0.03 remained positive after initiation of treatment was 5 days mg/mL by means of the same procedure. Vancomycin at con-(range, 5 -9 days). centrations of 128 mg/mL, 64 mg/mL, 32 mg/mL, 16 mg/mL, The antibiotic regimens and outcomes are summarized in 8 mg/mL, 4 mg/mL, and 2 mg/mL was added with sterile table 2. The mean number of days that CSF cultures remained 50-mL pipetors. Bacterial cultures incubated overnight were positive before administration of intravenous rifampin was 1.7 adjusted to a 0.5 McFarland standard, diluted 1:300 in MHB, days (range, 1 -3 days). The dosage of vancomycin varied from and added to each well in 100-mL volumes. Each plate was 45 mg/(kgrd) to 60 mg/(kgrd) every 6 -8 hours. The dosage incubated overnight at 35ЊC. Plates were inspected with a mirof rifampin for all infants was 20 mg/(kgrd) every 12 -24 ror, and visible turbidity was recorded. The MICs of all the hours. The mean duration of treatment with vancomycin was antibiotics alone and in combination were determined under 15 days (range, 6 -24 days), and that for rifampin was 24 days the same conditions for each isolate. The MIC was recorded (range, 20 -29 days). All of the neonates tolerated treatment as the lowest concentration of antibiotic that inhibited the with vancomycin and rifampin well, and no adverse effects growth of the organism, as determined by the lack of turbidity.
(abnormal liver function, rash, thrombocytopenia, or elevated The fractional inhibitory concentration (FIC) index was calculevels of blood urea nitrogen) were noted. All three neonates lated with the following formula [4] :
with meningitis due to F. meningosepticum survived without developing hydrocephalus or neurological deficits, as deter-FIC Å MIC antibiotic 1 in combination MIC antibiotic 1 alone mined on physical examination at the time of discharge. Two infants developed mild sensorineural hearing loss (30 dB). / MIC antibiotic 2 in combination MIC antibiotic 2 alone F. meningosepticum was recovered at birth in a tracheal aspirate from the premature infant. Bacteremia due to F. meningosepticum subsequently developed in this infant at 3 weeks of age Synergy was considered to be present if the FIC was õ0.5.
and resolved with a 10-day course of vancomycin and ceftaziIf the FIC was §0.5 and £1, the combination was considered dime. The infant died of Staphylococcus aureus septicemia at additive. Antibiotic interaction was considered indifferent 2 months of age. when the FIC ranged between ú1 and £2 and antagonistic if the FIC was ú2 [4] .
Susceptibility Testing Literature Search
MICs. The activities of ciprofloxacin and rifampin against the four strains of F. meningosepticum were superior to those We conducted a literature search by using MEDLINE with the subject heading Flavobacterium meningosepticum. We limof all other antimicrobial agents tested; MICs ranged from 0.125 mg/mL to 0.25 mg/mL and from 0.25 mg/mL to ited our search to the English-language literature from 1966 through 1997. Reference lists included in previous case reports, 1 .56 mg/mL, respectively ( strains of F. meningosepticum at concentrations of 2 -4 9. The interaction between meropenem and ciprofloxacin and rifampin was additive against all isolates (FIC range: 0.625 -mg/mL, while the MICs of vancomycin ranged from 16 mg/mL to 64 mg/mL. Meropenem consistently inhibited the 1). Linezolid showed additive effect against all isolates when combined with ciprofloxacin and vancomycin, with FICs ranggrowth of all isolates at 16 mg/mL. The MBCs ranged from 16 mg/mL to 32 mg/mL for vancomycin and meropenem, while ing from 0.62 to 1. The combination of linezolid and rifampin was equally additive or indifferent. Table 4 summarizes these 32 -128 mg/mL of linezolid were required for bactericidal effect. Rifampin and ciprofloxacin showed the lowest MBCs.
results. Three strains were resistant to cefotaxime. Two strains were susceptible TMP-SMZ, and three were resistant to piperacillin. Table 3 shows a comparison of the MIC results for the antimicrobial agents tested.
Literature Review
In 1980, Dooley et al. [2] summarized 63 previously reported cases of F. meningosepticum meningitis that occurred from Broth microdilution synergy studies. With use of the checkerboard microtiter technique, a synergistic interaction between 1944 to 1976. Of 52 infants for whom the outcome of infection was known, 34 (65%) died. Of the 18 neonates who survived, vancomycin and rifampin was found among three isolates tested (75%), while the combination of vancomycin and ci-11 (61%) developed hydrocephalus. Three additional cases were not included in that review, and nine additional cases profloxacin showed an additive effect for all strains. The combination of vancomycin and meropenem was antagonistic when were described in the literature from 1980 to 1995 [3, 5 -13] . Pertinent data on clinical findings, laboratory results, antimicrotested against all four isolates, with FICs ranging from 3 to NOTE. Data are mg/mL. National Committee for Clinical Laboratory Standards breakpoints for gram-negative bacteria are as follows: cefotaxime, £8 mg/mL; piperacillin, £16 mg/mL; ciprofloxacin, £1 mg/mL; TMP-SMZ, £2/38 mg/mL; meropenem, £4 mg/mL; and linezolid, data not available. TMP-SMZ Å trimethoprim-sulfamethoxazole.
bial therapy, and outcomes for these additional 12 patients are among the four species of the genus Flavobacterium. Detailed microbiological characteristics have been previously described summarized in table 5. The mean age of these 12 patients at presentation with F. meningosepticum meningitis was 7.4 days, [14, 15] . It is important for clinicians to remember that F. meningosepticum should be suspected when an unidentified, and the majority were male (78%). Overall, four (50%) of eight catalase-and oxidase-positive gram-negative rod that is resisneonates whose length of gestation was known were full-term tant to multiple antibiotics is isolated. Although an unusual infants. According to the available data, the mean time that pathogen of neonatal sepsis, F. meningosepticum can cause CSF cultures remained positive was 16 days (range, 8 -39 meningitis and is a potential cause of significant morbidity and days); 10 (100%) of 10 infants had associated bacteremia. One mortality in this age group. F. meningosepticum has also been death was related to infection due to F. meningosepticum, reimplicated as the etiology of nosocomial pneumonia [16] , endosulting in a case fatality rate of 8.3%. Hydrocephalus developed carditis [17, 18] , and postoperative bacteremia in adults [19] . in 70% of the surviving infants. Five patients received intratheHowever, neonatal meningitis remains the most serious human cal antibiotics.
infection because of its association with hydrocephalus in When our three patients with meningitis were included in the 60% -70% of the reported cases and its epidemic potential in analysis, the risk ratio for developing hydrocephalus was 3.5 nurseries. Of the six serotypes that have been identified, serotimes higher for the infants who received intraventricular therapy type C causes most human infections [14] . Neonatal outbreaks than for those who received intravenous antibiotics alone of F. meningosepticum serotypes C, E, and F have been re-(P Å .028; 95% CI Å 1.08, 11.29). However, the strength of the ported in association with contamination of the hospital enviassociation between the occurrence of hydrocephalus and positive ronment, including antiseptic solutions, vials of intravenous CSF cultures for ú10 days was stronger (P Å .0005).
drugs, chlorinated water sources, and respiratory equipment [6, Discussion 11, 14]. The clinical presentation of F. meningosepticum meningitis F. meningosepticum is a water-borne, gram-negative, rarely encapsulated rod, and it is the most relevant human pathogen does not differ from that associated with other common patho- [2] .
Implementing the appropriate antibiotic therapy can be a vancomycin. Both patients survived but developed hydrocephalus. difficult task for clinicians, since F. meningosepticum is susceptible to antibiotics frequently used for infections due to gramFrom 1977 through 1995 there were no reports of treatment of F. meningosepticum meningitis with vancomycin. In 1995, positive microorganisms. Antimicrobial agents such as erythromycin, clindamycin, piperacillin, chloramphenicol, imipenem, Tizer et al. [3] reported a successful neurological outcome for a 1-month-old infant with F. meningosepticum meningitis who TMP-SMZ, clindamycin, vancomycin, and rifampin have been suggested in the literature as therapeutic options for F. meninwas treated with intravenous vancomycin in combination with rifampin. We describe three additional infants who were sucgosepticum infection [1, 2, 5 -14, 20] . Moreover, there is no consensus on standardized susceptibility breakpoints for these cessfully treated for F. meningosepticum meningitis: two with intravenous vancomycin and rifampin and the third with intraantibiotics in regard to this pathogen, and in some cases, clinical response has been satisfactory even in the presence of high venous rifampin in combination with TMP-SMZ. Sterilization of the CSF was achieved after 5 -9 days of total antibiotic MICs. When feasible, antimicrobial susceptibility should be confirmed with use of a quantitative method, since routine therapy, 3 -6 days of vancomycin therapy, and 1 -3 days of rifampin therapy. None of these neonates developed hydrodisk diffusion techniques are not reliable for flavobacteria [20] . Emergence of resistance to any antimicrobial agent can develop cephalus.
The toxicity of the early compounds and the high levels of during therapy, and monitoring MICs during treatment is required to appropriately modify antibiotic management when endotoxin released as a result of intrathecal antibiotic therapy [26] could explain the adverse neurological outcomes seen duran infection persists. Table 5 summarizes case reports published in the Englishing the earliest experiences with vancomycin and other intraventricular antibiotics. To our knowledge, no previous studies language literature over the last 20 years. Chang et al. [21] recently reported the results when 41 isolates of F. meningosepof synergistic antibiotic activity against F. meningosepticum have been reported. Our in vitro synergy studies support the ticum were tested against several antimicrobial agents. The MIC 90 of cefotaxime was ú128 mg/mL; thus, this drug was clinical evidence that intravenous therapy with vancomycin and rifampin represents an appropriate regimen for the managenot recommended as the first choice for treatment of infections due to this organism [21] . The majority of the isolates were ment of neonatal meningitis due to F. meningosepticum. This recommendation should be considered even when the MICs of susceptible to piperacillin, and 90% of them were inhibited by £8 mg/mL of the drug. However, these results are higher than vancomycin are £32 mg/mL, since in vitro, rifampin lowers these values to therapeutically achievable levels in the CSF the achievable concentration of piperacillin in the CSF [22] , and piperacillin is recommended only for treatment of selected [27] . Moreover, the MIC breakpoints for vancomycin that have been recommended by the NCCLS are for gram-positive organcases of meningitis due to gram-negative bacilli [23] . Furthermore, in two of the reported cases, the patients received piperaisms and might not be appropriate for interpreting the MICs for Flavobacterium species [21] . cillin but developed hydrocephalus [11, 13] . A report of 11 cases of F. meningosepticum neonatal meningitis found in the The newer quinolones might be promising agents for the treatment of F. meningosepticum infection [28, 29] . Canton et Chinese-language literature described six neonates treated with piperacillin; one died, and three developed hydrocephalus [24] .
al. [28] compared in the vitro activity of six quinolones against seven clinical isolates of Flavobacterium species. Sparfloxacin, Of all the therapeutic alternatives described in the literature, the combination of vancomycin and rifampin seems the most followed by ciprofloxacin, had the greatest activity: MIC 90 values were 0.25 mg/mL and 0.5 mg/mL, respectively. Our studies appropriate on the basis of the outcomes in the reported cases and in our own cases. In 1961, George et al. [25] described have corroborated these results. The mode MIC of ciprofloxacin was comparable to that of rifampin (mode MIC, 0.25 the largest outbreak of neonatal meningitis due to F. meningosepticum, as well as the use of vancomycin intravenously or mg/mL) and 128-fold less than that of vancomycin (mode MIC, 0.25 mg/mL vs. 32 mg/mL). Ciprofloxacin in combination with intrathecally or both. The overall case fatality rate among the infected infants was 64%. Although the number of patients vancomycin had an additive effect against all four isolates of F. meningosepticum that were tested. However, these quinotreated with parenteral antibiotics was limited and interpretation of these values might be misleading, the case fatality rate lones have not yet been approved for use in children, and further research is needed to determine the clinical efficacy of for those infants who received vancomycin was 33%, compared / 9c4c$$my57 04-10-98 01:59:35 cida UC: CID NOTE. Amp Å ampicillin; Azl Å azlocillin; Carb Å carbenicillin; Chl Å chloramphenicol; Cm Å clindamycin; CS Å cesarean section; Ctox Å cefotoxime; Em Å erythromycin; Gm Å gentamicin; GNR Å gram-negative rods; Km Å kanamycin; NA Å data not available; Rif Å rifampin; SVD Å spontaneous vaginal delivery; Tic/Clv Å ticarcillin/clavulanate; TMP-SMZ Å trimethoprim-sulfamethoxazole; / Å positive.
quinolones, alone and in combination for the treatment of F.
breakpoint. However, bactericidal concentrations were compameningosepticum infections.
rable to those obtained with vancomycin and meropenem, with Meropenem, a new carbapenem effective against a broad a mode MBC of 32 mg/mL for all three antimicrobials. The spectrum of gram-positive and gram-negative pathogens, has combination of linezolid, which has dominant bacteriostatic been recently approved for treatment of meningitis in children action, and ciprofloxacin, a strongly bactericidal agent, de- [30, 31] . However, in these studies all isolates were inhibited serves further study to assess its clinical efficacy. at a concentration of 16 mg/mL and were considered resistant.
The results of in vitro synergy studies may suggest that Meropenem alone is unlikely to be efficacious for neonatal certain combinations of antibiotics are more useful clinically meningitis due to F. meningosepticum. The combination of than others. However, it is important to assess the correlation meropenem and vancomycin against F. meningosepticum was between clinical data and laboratory results. The results of strongly antagonistic and should be avoided in clinical practice. some in vitro synergy studies have not correlated with the Linezolid is an oxazolidinone, a new class of antibacterial clinical outcomes observed for patients. This has been the case agents especially active against multidrug-resistant gram-posiwith the use of TMP-SMZ to treat enterococcal infections [35] . tive microorganisms such as methicillin-resistant S. aureus and In other instances the recognition of synergy between penicillin Staphylococcus epidermidis as well as vancomycin-resistant and gentamicin in the treatment of serious infections due to Enterococcus species [32] . These compounds are bacterial proenterococci has a significant impact on the clinical outcome tein synthesis inhibitors. Although the MIC breakpoint for susfor patients [36] . ceptibility has not been established, the MICs at which 50%
In conclusion, we found that clinical data and in vitro studies and 90% of gram-positive bacteria are inhibited are 2 mg/mL indicate that the combination of intravenous vancomycin and and 2 to 4 mg/mL, respectively [33, 34] . All isolates of F.
rifampin should be considered as the initial empirical therapy meningosepticum were inhibited by 4 mg/mL of linezolid and for F. meningosepticum meningitis in newborns. The in vitro activity of quinolones and oxazolidinones alone and in combiwere considered susceptible on the basis of the estimated / 9c4c$$my57 04-10-98 01:59:35 cida UC: CID
